News >

Less Frequent Zoledronic Acid Not Linked to Increased Skeletal Events for Patients With Bone Metastases

Ellie Leick
Published: Sunday, Jan 08, 2017

Andrew L. Himelstein, MD

Andrew L. Himelstein, MD

Among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, those who used zoledronic acid every 12 weeks, compared with the standard dosing interval of every 4 weeks, did not experience an increased risk of skeletal-related events (SREs) over 2 years. These findings come from a recently published study in the Journal of the American Medical Association.

He added that, “Denosumab appears to be slightly more effective than zoledronic acid. It's also a lot more expensive. At the time, dosing requires monthly visits to the doctor with injections under the skin. At some point, future research could look at less frequent zoledronic acid directly compared to denosumab.”
Himelstein AL, Foster JC, Khatcheressian L, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases. JAMA. 2017;317(1):48-58.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication